Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with the recent investments in Enara Bio, ArsenalBio, Kyverna and Artiva signifies that the field is poised to regain momentum. It’s not just investments that are gaining traction. Recent approvals are changing […]

4th mRNA Analytical Development & Quality Control Summit | February 25-27, 2025 Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running. Yet, despite optimized analytics, critical quality control methodology and robust assay development leading to efficient approvals and commercialization, knowledge gaps persist in phase-appropriate assays, analyzing […]

The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology, Radionetics and Aktis Oncology, the field is turning to cutting-edge, novel targeting molecules and new targets to address more unmet medical need. With […]

2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data, expansion into autoimmune disease, and combination approaches all take off! So, we are proud to announce the 10th Anniversary Innate Killer Summit returning to San Diego this March, to showcase all […]

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge in multi-billion-dollar acquisitions, commercialisation deals, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments […]

In the current cell therapy landscape, where funding is tight and clinical development a priority, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency Assay Summit, uniting AD, QC and regulatory experts, this summit works to design potency assays that not only conform to changing guidelines but also streamline […]

The 6th Supply Chain & Logistics for Cell & Gene Therapies Summit is the ultimate practical guide for designing scalable, traceable, and resilient global supply chains to support the growing number of complex cell and gene therapies. It is an industry wide challenge and vital part of development, to ensure safe and timely delivery to […]

Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However, challenges persist, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access, managing global supply chains, importation, licensing, […]

With Merck's acquisition of EyeBio for $1.3 Billion, Roche's Vabysmo launch success and multiple other phase II and III trials in DME, DR, RVO, and Wet AMD, there is plenty to discuss in the retinal vascular drug space as drug developers seek to new alternatives to anti-VEGF, explore biosimilars, and target retinal fibrosis and more […]

The field of conjugatable drugs is advancing at a rapid pace, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals, which paves the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs. The 4th Novel Conjugates Summit is the only event offering comprehensive […]

With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases. Returning to Boston in March, the 8th Gene Therapy Development Summit, formerly known as the Gene Therapy for Rare […]

In today’s complex drug development landscape, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through the drug development pipeline. The 2nd Biophysics for Drug Discovery Summit is your exclusive opportunity to unite and network with your biophysics and drug discovery […]

As the biopharma industry evolves with rapid advancements in drug development, manufacturing, and research, EHS leaders are tasked with safeguarding employee health, maintaining a culture of safety, and addressing environmental concerns. Navigating these challenges while meeting sustainability goals and mitigating risks has become essential for operational success. EHS professionals must continuously adapt to this dynamic […]

Over the past year, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca, and Parvus and AbbVie, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have […]

The 2nd DNA Process Development & Manufacturing Summit: Accelerating Innovative Advanced Therapies with Revolutionary Plasmid & Enzymatic DNA. With the plasmid DNA manufacturing market set to rise to $39.3Bn by 2033, and the demand for advanced therapies continuing to surge as gene therapy reaches new heights and DNA vaccines promise to transform outbreak response, there has […]

With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use, nasal delivery is opening a new era of more efficient drug and vaccine administration with life-saving potential. However, challenges in biologics formulation, along with renewed interest from major pharmaceutical companies […]

The 2nd Peptide-Based Therapeutics Summit will return to Boston in April 2025, bringing together over 80 experts in peptide computational science, medicinal chemistry, and formulation to discuss the latest advancements shaping the next generation of peptide-based therapies—from early-stage discovery to clinical application. Download the three-day program here: https://ter.li/rrvg1v This year’s summit will highlight groundbreaking innovations […]

Returning as the only event created selectively for and by the TCR community, the 6th TCR-based Therapies Summit (April 1-3, 2025 | Boston, MA) is your unique opportunity to connect and collaborate with TCR developers and experts to battle the specific discovery, preclinical and clinical challenges created by T cell receptor biology to advance cell- […]

As recent advances in small molecules, ADCs, cell, and gene therapies poise novel precision therapies from the bench to the clinic, the 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the industry-leading end-to-end forum for Europe’s precision medicine community. Over three days, 170+ key stakeholders from across Europe working in Biomarkers, Translational […]

Welcome to the first ever Tumour Models Summit Nordics. This April, the critically acclaimed Tumour Models series will be coming to the Nordics for the first time ever, uniting more than seventy pharma, biotech, and research leaders across the Nordic biotech landscape. The inherent heterogeneity of cancer - both inter-patient and intra-tumoral – remains a significant challenge in cancer modelling. With only 5% of cancer drugs successfully advancing to clinical trials, there is […]

LEAP HR: Life Sciences West is your chance to explore how leading and emerging biopharma organizations are navigating industry volatility and preparing for the workforce of tomorrow. As the sector recovers from funding challenges and workforce reductions, discover innovative ways to align your HR strategy with evolving business needs in 2025 and beyond. Join 200+ […]

Unlock the Future of ADC Analytics at the 4th ADC Analytical Development Summit! When: April 2025 Where: Boston The 4th ADC Analytical Development Summit is back, bringing together top minds and innovators to tackle the unique analytical challenges of antibody-drug conjugates. With ADCs becoming more complex and regulatory requirements tightening, this event will be your ultimate guide to mastering […]

As the healthcare industry evolves, patient engagement has become a crucial factor in shaping clinical trials, accelerating regulatory approvals, and improving the overall patient experience. Yet, amidst a challenging funding environment, empowered patients rightfully demanding greater involvement in treatment decisions, and regulatory bodies requiring transparent reporting of patient engagement activities, it has become more critical […]

The 2nd GLP-1-Based Therapeutics Summit is an exclusive gateway to competitive intelligence into the continued potential of cutting-edge GLP-1s for obesity, weight loss, diabetes, and beyond. Join us to hear the latest clinical data on combination therapies to enhance muscle preservation, indication expansion into new areas, and strategies to improve the efficacy, tolerability, and durability of GLP-1s. With […]

The 3rd mRNA Process Development & Manufacturing Summit 2025 returns as Europe’s premier industry-focused forum, dedicated to optimizing process development for mRNA therapeutics and vaccines. This event will address end-to-end process optimisation, regulatory compliance to streamline approvals, while also advancing scalable and cost-efficient manufacturing solutions, to support drug developers in delivering safer and more effective mRNA drugs […]

The 2nd ADC Payload Summit (May 6-8 | Boston, MA) is the first and only conference exclusively focusing on ADC payloads, helping you to reimagine the medicinal chemistry of traditional cytotoxic payloads while scouting the next generation of ADC payload innovations. With novel payload categories such as degraders, RNA polymerase II inhibitors, immunomodulators, gene silences, […]

The ALS Drug Development Summit is the definitive industry-led forum dedicated to advancing breakthroughs in ALS therapeutics. With the field evolving rapidly, recent milestones—such as Insitro’s AI-driven target discovery with Bristol Myers Squibb and Dewpoint Therapeutics’ collaboration with Mitsubishi Tanabe Pharma America on TDP-43 condensate modulators—highlight the momentum in novel drug discovery. Meanwhile, QurAlis’ clinical […]

Following a year of exceptional progress in IBD drug development, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high, and it’s time for biopharma to push the boundaries of efficacy and distinguish their therapies amongst the market. Featuring three days of data-driven sessions from 25+ world-class speakers, the 3rd Precision Medicine […]

From molecular glue discovery to the development of degrader-antibody conjugates, pharma is transforming through strategic transactions and by leveraging protein degradation technologies to expand target discovery and drug previously 'undruggable' targets. This provides biotech with the opportunity to understand pharma's targets of interest and the options for increased specificity and selectivity compared to traditional molecules. […]

The 4th GPCR-Targeted Drug Discovery Summit: Transforming the Discovery of Novel GPCR-Targeted Therapies. With positive clinical read outs by Tectonic Therapeutics and recent funding rounds for Confo Therapeutics & Septerna, the potential for novel GPCR drug classes to treat a plethora of diseases grows. Now more than ever, there is a need for the community […]